Gene Overview
• Gene:PYCR1(pyrroline-5-carboxylate reductase 1)
• Chromosomal location: 17q25.3
• Protein: Mitochondrial enzyme catalyzing the final step of proline biosynthesis — reduction of pyrroline-5-carboxylate (P5C) to proline, using NAD(P)H.
• Isoenzymes: Three human PYCR paralogs (PYCR1, PYCR2, PYCRL), but PYCR1 is the principal mitochondrial form expressed in fibroblasts and connective tissue.
Type and Distribution of Mutations
Missense mutations(most common)
p.Arg119Cys, p.Ala190Val, p.Gly248Arg, p.Gly287Arg, p.Arg251Cys
Disrupt enzyme folding, reduce catalytic activity, and destabilize mitochondrial localization
Nonsense / frameshift
p.Arg251*, p.Ser188fs, p.Leu227fs
Truncated non-functional protein; rare but reported
Splice-site variants
c.621+1G>A, c.752-2A>G
Abnormal transcript splicing and protein loss
Compound heterozygosity
Common — most affected individuals carry two distinct variants on different alleles
Typical in outbred populations
Most variants are missense substitutions in conserved residues within the NAD(P)H-binding or catalytic domain, impairing enzyme stability and mitochondrial targeting rather than completely abolishing expression.
Suspected Pathophysiologic Mechanism
Molecular / biochemical
Loss of PYCR1 activity → decreased conversion of P5C → proline; reduced NAD(P)H oxidation; impaired redox homeostasis
Cellular
Mitochondrial fragmentation, increased oxidative stress, and sensitivity to apoptosis in patient fibroblasts
Tissue / organismal
Impaired collagen and elastin cross-linking → defective elastic-fiber formation → cutis laxa and connective-tissue fragility
Clinical correlate
Progeroid skin changes, growth delay, and mild neurodevelopmental impairment with generally preserved viability
Diagnostic Testing
StepDescriptionNotes1. Molecular genetic testing
Gold standard:PYCR1sequencing (Sanger, NGS panel, or exome)
Detects biallelic pathogenic or likely pathogenic variants
2. Copy-number analysis
Targeted CNV detection (MLPA or NGS depth analysis)
Rare large deletions/duplications possible but uncommon
3. Biochemical testing (supportive)
Proline levels typically normal in plasma but decreased NAD(P)H-dependent proline formation in fibroblast assays
Confirms functional enzyme loss
4. Functional assays
Patient fibroblasts show fragmented mitochondria, increased ROS, reduced membrane potential
Research-level confirmation
5. Imaging / histology
Skin biopsy: sparse, fragmented elastic fibers on orcein/Verhoeff-Van Gieson stain
Non-specific but supports connective-tissue defect
6. Family studies
Segregation testing for carrier confirmation
25 % recurrence risk per pregnancy (autosomal recessive)
Molecular Differential Diagnosis
Key Distinguishing Features
ATP6V0A2
ARCL type 2A
Abnormal serum transferrin glycosylation; severe neurologic involvement
ALDH18A1
ARCL type 3 (De Barsy syndrome)
More severe progeroid appearance; often lethal infancy
PYCR2
Hypomyelinating leukodystrophy 10
Predominant CNS involvement, minimal cutis laxa
FBLN5, EFEMP2, LTBP4, ELN
Other ARCL forms
Distinct cardiovascular or pulmonary findings
Pathogenicity Evidence
• Functional complementation with wild-type PYCR1 rescues fibroblast mitochondrial morphology.
• Enzyme assays show 50–90 % reduction in catalytic activity in mutants.
• Knockdown models replicate cellular oxidative-stress phenotype.
• Classified as definitive gene–disease relationship by ClinGen (ARCL2B).